We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against the other stocks set to explode in 2025.
“Big Technology are The New Defensives” Strategist Says
As the Magnificent Seven continues to release earnings for the fiscal third quarter of 2024, investors are keen to see if the group can maintain their market leading position and exemplary performance. On October 25, Nancy Tengler, Laffer Tengler Investments CEO & Chief Investment Officer, appeared in an interview on Yahoo Finance to share her market thesis on big tech amid current market conditions.
Tengler suggests that names in big technology boast reliable earnings growth, fitting the basic criteria of such. She adds that she would much rather own big tech names than invest in traditional defensive stocks despite a sluggish economic backdrop. Tengler reiterates her bullish stance on the sector claiming that big technology names are the new defensive and hold much stronger positions in the market.
READ ALSO: 10 Oversold Tech Stocks To Buy Right Now and 8 Unstoppable Stocks That Could Make You Richer.
She emphasized that these names have large cash flow reserves, oftentimes, bigger than most countries. Tengler highlights that she is not bullish on all of the names in the magnificent seven and stresses that she has expanded her exposure to the tech sector, adding new stocks to her portfolio. However, at the same time, there are several names within the magnificent seven that cannot be ignored or argued against. She also suggests that investors must seek to invest and own a select few among the group, instead of owning all of them.
She shares that she was previously pessimistic about certain names she held and emphasized that she will focus on margins for certain stocks among the Mag Seven moving forward. Tengler also adds that while these companies have been criticized for pouring billions into capital expenditures, certain names are expected to benefit immensely from AI monetization and their unique cloud services and products.
While many characteristics define exploding stocks, some key traits involve an expanding customer base, improving monetization of offerings, increasing cash flows, and strong fundamentals. Biotech, electric vehicles, artificial intelligence, and cloud are among the few high-growth markets expected to blow up in the coming years. Within these sectors, certain names have been performing exceptionally well in the current market rally and are expected to outperform in 2025.
Our Methodology
To come up with 10 stocks set to explode in 2025, we consulted financial media to shortlist stocks that are expected to perform exceptionally well according to analysts and strategists. After consulting 10 similar rankings on the internet we examined the Street-High upside for each stock and picked the ones with the highest upside, as of October 27, 2024. Our list is in ascending order of the street high upside as of October 27, 2024. We have also mentioned the hedge fund sentiment for each stock.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases.
TG Therapeutics, Inc. (NASDAQ:TGTX)
Street High Upside as of October 27, 2024: 110%
Number of Hedge Fund Holders: 38
TG Therapeutics, Inc. (NASDAQ:TGTX) ranks fourth on our list of stocks expected to explode in 2025. The biotech company engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
BRIUMVI, a medicine for adults with relapsing forms of multiple sclerosis, is the company’s major product. In the second quarter of 2024, BRIUMVI sales reached $72.6 million, exceeding expectations. Consequently, the company raised guidance for the full-year sales to reach between $290 million and $300 million. Overall, company revenue reached $73.47 million, up by 357% year-over-year.
TG Therapeutics, Inc. (NASDAQ:TGTX) is making significant efforts to establish solid fundamentals for the company. During the second quarter of 2024, the company established a credit facility to pay its current debt and accelerate the initiation of a share repurchase program. In addition to that, the company is also focused on maintaining solid cash flow, improving marketing efforts, and developing a strong commercial infrastructure.
While the company reported a net loss of $6.9 million during the quarter and $3.8 million for the first half of the year, TG Therapeutics, Inc. (NASDAQ:TGTX) logged a net loss of $47.6 million and $86.8 million for the three and six months ending June 30, 2023. This suggests that the company is slowly closing its loss and will be expected to become profitable by next year. Analysts are also bullish on the stock and their high price target implies an upside of 110% from current levels.
Overall, TGTX ranks 4th among the 10 stocks set to explode in 2025. While we acknowledge the potential of TGTX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TGTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
